nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

18.07.2024 | short review

Trends in MDS and AML from ASH 2023

verfasst von: Prof. Dr. Michael Pfeilstöcker

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Summary

Presentations in the field of clonal myeloid diseases from the 65th American Society of Hematology conference provided insights into future therapeutic approaches especially for the subset of older patients. While new drugs and concepts for acute myeloid leukemia need further work before clinical implementation, some data on myelodysplastic neoplasms providing new treatment options for transfusion-dependent low-risk patients are already practice-changing.

Vorheriger Artikel American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

Nächster Artikel Liquid profiling for patients with advanced cancer is ready for clinical integration

Issa GC, Ravandi F, DiNardo C, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35:2482–95.CrossRefPubMed

Aldos I, Issa GC, Thirman M, et al. Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal augment-101 phase 2 study. LBA‑5. ASH 2023.

Issa GC, Cuglievan B, DiNardo CD, et al. Early results of the phase I/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in acute Myeloid leukemia (SAVE). Blood. 2023;142(Supplement 1):58.CrossRef

Jabbour E, Searle E, Abdul-Hay M, et al. A first-in-human phase 1 study of the Menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations. Blood. 2023;142(Supplement 1):57.CrossRef

Yang L, Chen F, Liang H, et al. Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit acute myeloid leukemia (AML): a multicenter, open-label prospective study. Blood. 2023;142(Supplement 1):55.CrossRef

Angelucci E, Deconinck E, Manteigas D, et al. Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm: updated results from a European named patient program. Blood. 2023;142(Supplement 1):547.CrossRef

Minetto P, Rosellini S, Guolo F, et al. Single agent Tagraxofusp in relapsed/refractory CD123-positive acute myeloid leukemia: a preliminary analysis of Italian Gimema AML2020 trial. Blood. 2023;142(Supplement 1):2918.CrossRef

Lane AA, Garcia JS, Raulston EG, et al. Tagraxofusp in combination with Azacitidine and Venetoclax in newly diagnosed CD123+ acute Myeloid leukemia, expansion cohort of a phase 1b multicenter trial. Blood. 2023;142(Supplement 1):4277.CrossRef

Nguyen D, Ravandi F, Wang SA, et al. A phase II study of Vibecotamab, a CD3-CD123 Bispecific T‑cell engaging antibody, for MDS or CMML after Hypomethylating failure and in MRD-positive AML. Blood. 2023;142(Supplement 1):322.CrossRef

10.

Choe H, Tomlinson BK, Gyurkocza B, et al. 131 I‑Apamistamab-led Allogeneic hematopoietic cell transplant significantly improves OS in patients with TP53 mutated R/R AML. Blood. 2023;142(Supplement 1):469.CrossRef

11.

Yilmaz M, Muftuoglu M, DiNardo CD, et al. Phase I/II study of Quizartinib, Venetoclax, and Decitabine triple combination in FLT3-ITD mutated AML. Blood. 2023;142(Supplement 1):158.CrossRef

12.

Ruhnke L, Schliemann C, Mikesch J‑H, et al. Venetoclax plus high-dose Cytarabine and Mitoxantrone (HAM-Ven) as salvage treatment for relapsed/refractory AML: updated results of the phase-I/II SAL relax trial. Blood. 2023;142(Supplement 1):160.CrossRef

13.

Bazinet A, Garcia-Manero G, Short NJ, et al. A phase 2 study of the fully oral combination of ASTX727 (Decitabine/Cedazuridine) plus Venetoclax for older and/or unfit patients with acute Myeloid leukemia. Blood. 2023;142(Supplement 1):833.CrossRef

14.

Atluri H, Mullin J, Takahashi K, et al. Phase Ib/2 study of oral decitabine/cedazuridine (ASTX727) and Venetoclax in combination with the targeted mutant IDH1 inhibitor Ivosidenib or the targeted mutant IDH2 inhibitor Enasidenib: 2023 update. Blood. 2023;142(Supplement 1):968.CrossRef

15.

Othman J, Potter N, Ivey A, et al. The benefit of allogeneic transplant in 1st complete remission in NPM1 mutated AML with or without FLT3 ITD is restricted to those testing MRD positive after induction—an analysis of the UK NCRI AML17 and AML19 studies. Blood. 2023;142(Supplement 1):425.CrossRef

16.

Orvain C, Bertoli S, Peterlin P, et al. Molecular relapse after first-line intensive therapy in patients with core-binding factor and NPM1—mutated acute myeloid leukemia—a Filo study. Blood. 2023;142(Supplement 1):421.CrossRef

17.

Guolo F, Fianchi L, Martelli MP, et al. Optimal duration of CPX-351 treatment and best timing for consolidation with Allogeneic stem cell transplantation: evidence from a large real-world Italian study. Blood. 2023;142(Supplement 1):731.CrossRef

18.

Mims A, Xie Z, Vasconcelos A, et al. Intensive chemotherapy (IC) followed by oral Azacitidine (AZA) maintenance versus venetoclax (VEN) plus AZA for patients (pts) with acute myeloid leukemia (AML): retrospective analysis of an electronic medical record (EMR) database in the United States. Blood. 2023;142(Supplement 1):550.CrossRef

19.

Smith BD, Lachowiez CA, Ambinder AJ, et al. A comparison of acute myeloid leukemia (AML) regimens: hypomethylating agents combined with Ivosidenib or Venetoclax in newly diagnosed patients with IDH1 mutations: a real-world evidence study. Blood. 2023;142(Supplement 1):971.CrossRef

20.

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona). https://classic.clinicaltrials.gov/ct2/show/NCT04401748..

21.

Garcia JS, Platzbecker U, Odenike O, et al. Efficacy and safety of Venetoclax in combination with Azacitidine for the treatment of patients with treatment-naive, higher-risk myelodysplastic syndromes. Blood. 2023;142(Supplement 1):319.CrossRef

22.

Tentori CA, Gregorio C, Robin M, et al. Clinical and genomic-based decision support system to define the optimal timing of Allogeneic hematopoietic stem cell transplantation in patients with Myelodysplastic syndromes (MDS). Blood. 2023;142(Supplement 1):197.CrossRef

23.

Mittelman M, Henry DH, Glaspy J, et al. Efficacy and safety of Roxadustat for treatment of anemia in patients with lower-risk Myelodysplastic syndrome (LR-MDS) with low red blood cell (RBC) transfusion burden: results of phase III Matterhorn study. Blood. 2023;142(Supplement 1):195.CrossRef

24.

Komrokji RS, Santini V, Fenaux P, et al. Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study. Blood. 2023;142(Supplement 1):194.CrossRef

25.

Garcia-Manero G, Platzbecker U, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with transfusion-dependent (TD) lower-risk Myelodysplastic syndromes (LR-MDS): full analysis of the COMMANDS trial. Blood. 2023;142(Supplement 1):193.CrossRef

26.

Reblozyl: highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761136s009lbl.pdf..

27.

Union Register of medicinal products for human use. Product information: Reblozyl. https://ec.europa.eu/health/documents/community-register/html/h1452.htm..

Titel: Trends in MDS and AML from ASH 2023
verfasst von: Prof. Dr. Michael Pfeilstöcker
Publikationsdatum: 18.07.2024
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-024-00984-8

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Open Access
review

Antibody–drug conjugates (ADC special)—part 2

editorial

Antibody–drug conjugates (ADCs) in lung cancer treatment

Open Access
short review

American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

short review

Importance of allogeneic stem cell transplantation in myelofibrosis

Open Access
short review

The molecular tumor board—a key element of precision oncology

Open Access
Diagnostik in der Onkologie
Redaktionstipp

Springer Medizin Österreich

Trends in MDS and AML from ASH 2023

Summary

Weitere Artikel der Ausgabe 3/2024

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Antibody–drug conjugates (ADC special)—part 2

Antibody–drug conjugates (ADCs) in lung cancer treatment

American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

Importance of allogeneic stem cell transplantation in myelofibrosis

The molecular tumor board—a key element of precision oncology

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Antibody–drug conjugates (ADC special)—part 2

Antibody–drug conjugates (ADCs) in lung cancer treatment

American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

Importance of allogeneic stem cell transplantation in myelofibrosis

The molecular tumor board—a key element of precision oncology